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Summary  and conclus ions 
In summary, there is an increasing body of  infor- 
mation compatible with the concept hat infectious 
agents contribute to the development o f  atherosde- 
rosis and to plaque instability and rupture. These 
possibilities are strengthened by the multiple investi- 
gations providing cellular and molecular mechanistic 
support for such roles and by investigations demon- 
strating that certain pathogens can exacerbate l sion 
development in animal models. It  is equally clear, 
however, that no simple relationship exists between 
infection and atherogenesis. As with other infectious 
diseases, the propensity for a given infectious agent 
to contribute to the development o f  atherosclerosis 
will depend on host-pathogen i teractions. This in 
turn will determine susceptibility to pathogen inflam- 
matory activity and therefore to atherogenic poten- 
tial. And if additional studies support an important 
antoimmtme component  o atherogenesis, the type 
of  hurnoral and cellular immune responses mounted 
by the host to infection may determine whether a 
particular pathogen will contribute to atherosclerotic 
lesion development in a particular host. 
As the case for a role o f  infection grows, the exist- 
ing paradigms to explain the natural history o f  the 
clinical manifestations o f  CAD can be expanded. For 
example, it had been appreciated many years ago that 
atherosclerosis does not progress as a slow gradual 
process, but rather that the underlying progressive 
nature o f  the disease is punctuated by intermittent 
acute exacerbations. This has been appreciated both 
in the clinic and by morphologic investigations ofath- 
erosclerotic plaques. The concept hat infection plays 
a role in atherosclerosis fits this model  very well. 
Thus, with the product ion of  persistent subclinical 
infections causing a chronic inflammatory state (lead- 
ing to activation of  inflammatory cells and of  immune 
processes), infectious agents could contribute to grad- 
ual plaque enlargement. However, punctuation of  this 
low-grade persistent activity by recurrent acute infec- 
tions or intermittent reactivation of  latent infections, 
whether clinically overt or silent, could cause acute 
exacerbations o f the atherosclerotic process, including 
plaque rupture and thrombotic occlusion. 
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A goal o f  many vascular biologists has been to 
understand why smooth muscle ceils (SMCs) prolifer- 
ate. Early work focused on identification o f  mito- 
gen(s) that were thought necessary for SMC replica- 
tion, and while a great deal of  effort was expended, 
the conclusions from these studies have not benefited 
our understanding of  how lesions develop in man. In 
part this may reflect differences in animal models and 
in experimental conditions, but it also relates to an 
assumption that the response of  any SMC will be sim- 
ilar. I f  true then results obtained from experimenta- 
tion with a healthy artery o f a small mammal would 
be directly applicable to understanding cell replication 
in other arteries including those of  man. We have 
found this assumption to be incorrect but not neces- 
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sarily because of species differences. In this presenta- 
tion I will describe situations where the SMCs of rat 
arteries how very different behaviors. For example, 
FGF2 is a potent SMC mitogen when given to rats 
immediately after injury and is capable of stimulating 
SMC replication rates in excess of 70%. In contrast the 
same mitogen has almost no stimulatory effect on the 
SMCs of an arterial lesion. With these data, to there- 
fore conclude that FGF2 is an important mitogen for 
SMC growth is problematic. 1 We have also noted that 
reinjury of an established intimal esion by angioplas- 
ty induces ignificant increase in SMC replication that 
is not blocked by FGF2 antibodies or results in any 
increase in SMC number. 2 These data are just the 
opposite of what occurs when normal arteries are sub- 
jected to balloon catheter injury. This injury induces 
SMC replication, which is FGF2 dependent, and 
there is a significant increase in cell number. 3 To 
understand how SMCs can modify their response to 
various stimuli, we have begun to examine the signal 
transduction pathways activated in these cells. 4 
Immediately following balloon catheter injury, the 
extracellular-regulated kinase (ERK) pathway is acti- 
vated and remains so for approximately 24 hours. 
ERK1/2 are targeted by many mitogens, and their 
activation is linked to cell replication. The MEK1 
inhibitor PD 98059 was administered immediately 
prior to injury to demonstrate if this pathway is nec- 
essary for SMC replication in vivo, and a significant 
decrease in SMC replication was detected. 
Furthermore, an antibody to FGF2 reduced ERK 
activation. These data suggest hat FGF2, which is 
known to be responsible for the early SMC replica- 
tion, does so in part by the activation of the ERK 
pathway. 4 After balloon catheter injury, the medial 
SMCs are the first to replicate, but 4 to 7 days later, 
cells have migrated into the intima and continue to 
replicate at a high rate. There is almost no detectable 
increase in ERI( activation i  these cells, and adminis- 
tration of PD98095 at day 6 had no effect on the inti- 
real SMC replication. We have repeated this study 
using the more potent MEK1 inhibitor U01260 and 
obtained the same result. One conclusion, therefore, is 
that while medial SMCs use the ERK signaling path- 
way during replication, intimal cells do not. Another 
signaling pathway thought o play a role in cell repli- 
cation is the phosphoinositide 3-kinase pathway 
(PI3K). Activation of PI3K generates phosphoinositol 
diphosphate and triphosphate (PtdIns-P2 and PtdIns- 
p3L3,5), which trigger activation of downstream tar- 
gets including PKB, GSK-3b and p70s6k. Using phos- 
phorylation of PKB as an indicator of activation of this 
pathway, we have noted increased activity within 30 
minutes after injury as well as after 24 hours. Using the 
same approach as with the ERK pathway, a PI3K 
inhibitor, wortmannin significantly reduced any 
increase in the PI3K signaling after injury and also sig- 
nificantly blocked SMC replication between 24 and 48 
hours. Further administration f the inhibitor success- 
fully decreased the basal evel of PKB activation mea- 
sured after 6 days but had no effect on the replication 
of the intimal SMCs at this time. These data would 
support the conclusion that acutely after injury, the 
medial cells activate the PI3K signaling pathway, which 
in part, controls their replication. Furthermore the 
lack of PI3K activity and the ineffectiveness of wort- 
mannin demonstrate hat intimal SMCs do not use 
this signal transduction for their replication. Currently 
we are left with the situation that intimal SMCs reach 
high rates of replication without activation of the 
ERK, not the PI3K, pathways. How these cells enter 
the cell cycle is still not known. Another difference 
between rat SMCs relates to their ability to replicate in 
response to added mitogens. As mentioned above, the 
addition of FGF2 to acutely injured artery will drive 
replication in excess of 70%. The addition of FGF2 to 
rats whose arteries were injured 6 weeks previously, 
however, show only an increase in replication from 1% 
to 3%. To try and understand these differences, we 
examined the ERK signaling pathways and the ability 
of the cells to enter the cell cycle after the addition of 
FGF2 to these animals. Interestingly, SMCs of both 
sets of arteries howed a significant increase in ERK 
activation followed by an increase in cyclin D1; the lat- 
ter fact implied that the cells had entered the cell cycle. 
As would be predicted, the medial cells in the acutely 
injured arteries howed an increase in phospho-Rb, an 
increase in cyclin A expression, and a marked increase 
in cdk2 activity; these cells go on to replicate. In con- 
trast the cells comprising the intirna lesions (6 weeks 
after injury) show no Rb phosphorylation, no expres- 
sion of cyclin A, and no cdk2 activity after FGF2 
administration. Related to this fact is the finding that 
levels of two cyclin-dependent kinase inhibitors, name- 
ly p15INK and p27 Kipl, were significantly elevated. 
One consideration is that the presence of these 
inhibitors is responsible for the significantly reduced 
response of these SMCs to FGF2 stimulation. 
Currently we do not know why the levels of these 
inhibitors are differently expressed, but these data 
illustrate that the status of the artery can 
significantly modulate SMC responses to stimuli. 
Indeed we believe that confusion relating to the 
response of SMCs may be attributable to the local 
environment of the artery and not necessarily to 
species differences. 
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In the infrainguinal position, the primary paten- 
cy of synthetic vascular grafts lies between 30% and 
55%. 1-3 This disappointing outcome is opposed by a 
5-year primary patency of approximately 70% for 
saphenous vein grafts in a comparable patient 
group3 As a consequence, ndothelial seeding has 
been introduced with the goal to reduce the surface 
thrombogenicity of the prosthetic material through 
the creation of an autologous endothelial coverage. 
First attempts were based on a single-staged tech- 
nique, where freshly harvested venous endothelial 
cells were seeded. In clinical trials, however, single- 
staged seeding failed, most likely because of the low 
number of available ndothelial cells and the result- 
ing insufficient endothelial cell inoculum. 4 
In the 1980s two alternative techniques were 
developed that addressed this shortcoming: 
endothelial cell sodding 5 and in vitro endothelializa- 
tion. 6 While sodding exploits the abundance of 
microvascular endothelial cells in adipose fat tissue, 
in vitro lining achieves a similar goal through mass 
culture of venous endothelial cells. Our group has 
been involved with in vitro lining over the past 15 
years. 6-11 The present report summarizes almost 11 
years of clinical experience with close to 140 patients 
and describes our efforts to enhance graft perfor- 
mance in current clinical studies. 
Patients and methods 
With the clinical introduction of a new and tmtest- 
ed surgical treatment for peripheral rtery disease, our 
human trials had to be guided by three principle con- 
siderations: First, wc had to initially assume that vein 
grafts are superior to endothelialized ePTFE grafts 
before proved otherwise. Therefore, the study was 
confined to patients who had no venous conduit avail- 
able. Second, the standards established by Rutherford 
for studies involving new methods in vascular surgery 
required that only a limited number of patients be ini- 
tially randomized. We restricted the randomization of
the first phase of our study to less than 50 patients. 
The third determinant for the design of the study was 
the fact that autologous endothelial lining involves a 
time-dependent i  vitro procedure. Thus, our study 
was naturally restricted to patients with subacute or 
chronic peripheral occlusive disease. 
When the 3-year follow-up of the randomized 
phase 1 of our trial, as well as a similar study from 
another center, showed significantly better esults in 
the endothelialized group than in the control 
group, ethical considerations determined phase 2. 
Since the withholding of the treatment from 
patients with no saphenous vein available would not 
have been justified against he background of the 
phase 1 results, we decided to offer the treatment as 
a routine procedure to all nonacute patients who 
relied on ePTFE prostheses. Eventually, after 10 
years of clinical phase 1 and 2 trials including 152 in 
vitro endothelialized ePTFE grafts, it became safe 
to conclude that in vitro endothelialized ePTFE 
grafts perform similarly to autologous vein grafts. 
As a result, phase 3 of the study was initiated as a 
European multicenter study in which endothelial- 
ized ePTFE grafts are being compared with saphe- 
nous vein grafts in thc challenging below-knee posi- 
tion. Prior to the commencement of this random- 
ized multicenter study, we aimed at the further 
improvement of the shear stress resistance of the 
lined endothelium through the use of an RGD- 
enriched, engineered fibrin matrix as a precoating 
substrate. 
Phase 1 
From mid 1989 and onward, 49 patients were 
randomized. Details of this study were previously 
reported. 9 Indications for surgery were disabling 
claudication in 37 patients (grade I chronic limb 
ischemia) and chronic limb ischemia in 12 patients 
(grade II in six patients and grade III in six patients). 
For endothelial cell harvest, the right external jugu- 
lar vein was taken under local anesthesia. Mass cul- 
ture of first-passage endothelial cells was performed 
with first-passage endothelial cells until the required 
